AcouSort launches new project with Instrumentation Laboratory
AcouSort has since 2018 worked together with Instrumentation Laboratory (IL) on the integration of its technology into one of IL’s in vitro diagnostics systems. AcouSort will now initiate its third project related to supporting this integration. The specific project will generate revenues of about 100 000 USD for AcouSort.
– We are very excited about launching yet another project together with IL. Since 2015, we have had a very successful collaboration, and including this a total of seven joint projects. We are happy and proud that IL recognizes us as world-leading experts within our field. Strategic collaborations with companies like IL are a major part of our long-term business strategy. We now take another step towards realizing our ambition of making and securing our technology as the preferred method for automated sample preparation for the life science industry, says AcouSort’s CEO Torsten Freltoft.
IL is a world leading diagnostics company with several products within critical care and hemostasis. In 2018, AcouSort signed a license and distribution agreement involving the implementation of AcouSort’s technology into next generation of one of IL’s product families. The new project is a research and development project related to this agreement and involves investigating a future product modification.
This information is such information that Acousort AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on October 5, 2021.
For further information on AcouSort, please contact:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com
About AcouSort
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.